PharmaMar presents positive results with ADC MI130110 in CD13-expressing tumor cells

(Pharmamar) PharmaMar, a world leader in the discovery, development and commercialization of new anti-tumor compounds of a marine origin, has announced that its antibody-drug conjugate (ADC) has demonstrated a remarkable in vitro antitumoral activity in a CD13, fibrosarcoma positive animal model.